 Home > Active Ingredient News > Antitumor Therapy > Lancet Oncol: Efficacy of dabrafenib combined with trametinib in BRAFV600E mutation-positive glioma

Lancet Oncol: Efficacy of dabrafenib combined with trametinib in BRAFV600E mutation-positive glioma

 Last Update: 2021-12-04
 Source: Internet
 Author: User

Tags

orilissa side effects

denosumab side effects

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Glioma is the most common primary brain tumor
.

The 2016 WHO standard classifies gliomas into different subtypes and grades based on histological, molecular and genetic characteristics (especially IDH mutation status and 1p/19q deletion)

This study is an open-label, single-arm Phase 2 study conducted in 27 locations in 13 countries to evaluate the use of dabrafenib in combination with trametinib for high-grade BRAF ^V600E mutations that are positive for recurrent or progressive BRAF ^V600E mutations.
And the activity and safety of low-grade gliomas
.

^V600E

The study recruited 18-year-old patients with high-grade or low-grade glioma with EOCG performance status of 0-2 and BRAF ^V600E mutations and were given darafenib (150 mg, 2/day) + trameti Nitraria (2 mg, 1/day) is treated until intolerable toxicity, disease progression, or death occurs
.

What is in the hospital is the objective response rate assessed by the investigator

^V600E

Progression-free survival and overall survival of patients with high-grade glioma

From April 17, 2014 to July 25, 2018, the high-grade glioma cohort recruited 45 patients (of which 31 were glioblastomas), and the low-grade glioma cohort recruited 13 patients
.

As of September 14, 2020, the high-grade glioma cohort had been followed up for a median of 12.

The high-grade glioma cohort was followed up for a median of 12.

Progression-free survival and overall survival of patients with low-grade glioma

Thirty-one (53%) patients reported side effects of grade 3 and above, the most common being fatigue (5 cases [9%]), decreased neutrophil count (5 cases [9%]), headache (3 cases) [5%]) and neutropenia (3 cases [5%])
.

In conclusion, dabrafenib combined with trametinib has shown clinically significant therapeutic activity in relapsed or refractory high-grade gliomas and low-grade gliomas carrying BRAF ^V600E mutations, and the safety can be
.

Darafenib combined with trametinib has shown clinically significant therapeutic activity in relapsed or refractory high-grade gliomas and low-grade gliomas carrying BRAF ^V600E mutations, and the safety is good
.

Original source:

Patrick Y Wen, et al.

Dabrafenib plus trametinib in patients with BRAFV600E- mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.